Skip to main content
Log in

Clinical Trials: Rethinking How We Ensure Quality

  • Clinical Trials
  • Published:
Drug information journal : DIJ / Drug Information Association Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Califf RM. Clinical trials bureaucracy: unintended consequences of well-intentioned policy. Clin Trials. 2006;3:496–502.

    Article  Google Scholar 

  2. US Food and Drug Administration. Pharmaceutical quality for the 21st century: a risk-based approach progress report. March 9, 2010. https://doi.org/www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm128080.htm. Accessed October 1, 2012.

  3. International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: quality risk management Q9, current step 4 version (ICHQ9). November 2005. https://doi.org/www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf. Accessed October 1, 2012.

  4. Morrison B, Behrman R, Landray M; on behalf of Clinical Trials Transformation Initiative Monitoring Project. Results and recommendations: effective and efficient monitoring as a component of quality assurance in the conduct of clinical trials. May 20, 2011. https://doi.org/www.ctti-clinicaltrials.org/project-topics/study-quality/effective-and-efficient-monitoring-as-a-component-of-quality/results-and-recommendations. Accessed October 1, 2012.

  5. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), and Center for Devices and Radiological Health (CDRH). Guidance for industry: oversight of clinical investigations—a risk-based approach to monitoring. August 29, 2011 https://doi.org/www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM269919.pdf. Accessed October 1, 2012.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Martin J. Landray PhD, FRCP.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Landray, M.J., Grandinetti, C., Kramer, J.M. et al. Clinical Trials: Rethinking How We Ensure Quality. Ther Innov Regul Sci 46, 657–660 (2012). https://doi.org/10.1177/0092861512464372

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/0092861512464372

Keywords

Navigation